Table 3 Demographic, clinical characterstics and laboratory test results at admission and outcome data of the ICU and non-ICU patients
Patients never admitted to ICU n = 23 (43.4%) | Patients admitted to ICU n = 30 (52.6%) | p | |||
|---|---|---|---|---|---|
Demographic and clinical characteristics at admission, n (%) | |||||
Age in years, median (min.-max.) | 6.5 (19 months-17 years) | 8 (5 weeks-17 years) | 0.586 | ||
Male sex | 12 (52.2%) | 20 (66.7%) | 0.337 | ||
Comorbidities, n (%) | 6 (26.1%) | 5 (16.7%) | 0.501 | ||
Fever, days at admission, median | 5 | 5 | 0.8 | ||
Gastrointestinal symptoms | 14 (60.9%) | 24 (80%) | 0.2 | ||
Mucocutaneous symptoms | 17 (73.9%) | 23 (76.7%) | 0.922 | ||
Cardiovascular symptoms | 13 (56.5%) | 17 (56.7) | 0.528 | ||
Respiratory symptoms | 4 (17.4%) | 15 (50%) | 0.085 | ||
Neurological symptoms | 1 (4.3%) | 4 (13.3%) | 0.999 | ||
Renal symptoms | 1 (4.3%) | 8 (26.7%) | 0.005 | ||
SARS-CoV-2 test results, n (%) | |||||
Positive RT-PCR | 4 (17.4%) | 8 (26.7%) | 0.613 | ||
Positive serology | 18/22 (81.8%) | 24/29 (82.8%) | 0.723 | ||
Laboratory confirmed SARS-CoV-2 infection | 19 (82.6%) | 28 (93.3%) | 0.385 | ||
Epidemiological link to confirm SARS-CoV-2 infection | 9 (39.1%) | 11 (36.7%) | 0.579 | ||
Cardiogical disorders, n (%) | |||||
Myocardial dysfunction | 13 (56.5%) | 17 (56.7%) | 0.788 | ||
Coronary artery abnormalities | 2 (8.7%) | 4 (13.3%) | 0.687 | ||
Coronary artery aneurysm | 0 | 0 | N.A. | ||
Mitral valve regurgitation | 7 (30.4%) | 7 (23.3%) | 0,79 | ||
Pericardial effusion | 3 | 6 | 0.715 | ||
Abnormal ECG | 3 (13%) | 6 (20%) | 0.715 | ||
Laboratory test at admission (normal range), median (IQR), % of aberrant values | |||||
Platelets (150–400 Giga/L) | 276 (224–365) | 34.78% | 235 (121.25-273.75) | 48.39% | 0.284 |
WBC count (4.5–11.5 Giga/L) | 15.3 (9.46–17.51) | 0.00% | 11.28 (7.97–14.46) | 54.84% | 0.098 |
Absolute lymphocyte count (0.9-4 Giga/L) | 1.77 (1.23–3.03) | 21.74% | 1.2 (0.9–1.97) | 32.26% | 0.993 |
C-reactive protein (< 2.2 mg/L) | 167.14 (103.32-229.71) | 91.30% | 170.6 (104.04-205.63) | 100.00% | 0.813 |
PCT (< 0.5 ug/L) | 1.445 (0.4–3.08) | 56.52% | 2.6 (0.87–6.27) | 87.10% | 0.2 |
Interleukin-6 (< 7 ng/L) | 199.15 (109.17-315.25) | 82.61% | 202.9 (52.78–332.9) | 96.77% | 0.736 |
Cardiac TnT (< 10 ng/L) | 23.79 (17.14–37.85) | 56.52% | 20.62 (10.17–54.79) | 74.19% | 0.666 |
Pro-BNP (< 191.1 ng/L) < 191.,1 | 2396.71 (224.53-7320.38) | 65.22% | 2759.415 (1565.81-9188.5) | 87.10% | 0.718 |
Fibrinogen (1.5-4 g/L) | 7.97 (6.7–8.65) | 78.26% | 6.81 (4.53–8.07) | 87.10% | 0.031 |
Ferritin (13–150 ug/L) | 355.3 (188.3-482.1) | 69.57% | 546.8 (378.45-762.05) | 83.87% | 0.034 |
INR | 1.01 (0.96–1.04) | N/A | 1.09 (0.98–1.14) | N/A | 0.047 |
D-dimer (< 0.5 mg FEU/L) | 1.615 (1.28–2.29) | 82.61% | 3.82 (2.28–6.52) | 96.77% | 0.032 |
Albumin (35–52 g/L) | 36 (31.75-40) | 39.13% | 32.5 (29-35.75) | 48.39% | 0.084 |
Urea (1.4–6.8 mmol/L) | 3.85 (3.12–6.1) | 13.04% | 5 (3.8–6.9) | 25.81% | 0.127 |
Creatinine (26–88 umol/L) | 38.5 (33-46.75) | 0.00% | 48 (31–59) | 12.90% | 0.181 |
GPT (< 40 U/L) | 19.5 (13.75-28) | 13.04% | 23 (14-39.75) | 22.58% | 0.413 |
Bicarbonate (24 mmol/L) | 23.35 (22.45–25.5) | 4.35% | 25.05 (23.62–27.1) | 19.35% | 0.807 |
Clinical outcome, n (%) | |||||
Days of pediatric intensive care unit (median) | 0 | 5 | N/A. | ||
Oxygen therapy | 1 (4.3%) | 7 (23.3%) | 0.118 | ||
Respiratory support | 0 | 5 (16.67%) | 0.001 | ||
Vasoactive drugs | 0 | 18 (60%) | N/A | ||
Death | 0 | 0 | N/A | ||